Vertex Pharmaceuticals (VRTX) , along with CRISPR Therapeutics (CRSP) , announced that the FDA expanded the label of their one-shot gene therapy Casgevy to treat transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older.The approval comes just a month after the FDA approved the therapy for sickle cell disease (SCD) in the same age group. Following this initial approval, Casgevy became the first gene therapy utilizing the Nobel prize-winning CRISPR technology. This technology can selec ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. “ On the heels of the historic FDA approval of CASGEVY for sickle cell disease, it is exciting to now secure approval for TDT well ahead of the PDUFA date,” said Reshma Kew ...

TROY, Mich., Jan. 10, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) as its "Stock to Study" and Martin Marietta Materials Inc. (NYSE: MLM) as its "Undervalued Stock" in the March 2024 issue for investors' informational and educational use. "The S&P500 Index notched a total return gain of more than 26% in 2023, although a small number of individual stocks had an outsize influence over the inde ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $421.01, reflecting a +0.45% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.15% loss on the day. At the same time, the Dow lost 0.42%, and the tech-heavy Nasdaq gained 0.09%.The drugmaker's shares have seen an increase of 17.64% over the last month, surpassing the Medical sector's gain of 6.58% and the S&P 500's gain of 3.5%.The investment community will be paying close attention to the ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the Saudi Food and Drug Authority (SFDA) granted Marketing Authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). CASGEVY is approved for the treatment of people 12 years of age and older with SCD or TDT. The Kingdom of Saudi Arabia has among the highest prevalence rates o ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Jessica Fye - J.P. Morgan Conference Call Participants Reshma Kewalramani - Chief Executive Officer and President Jessica Fye Good morning, everyone. We're going to get started. My name is Jess Fye, I'm a Senior Biotech Analyst at J.P. Morgan, continuing the 42nd Annual Healthcare Conference this morning with Vertex. I'm joined by the Company's CEO, Reshma Kewalram ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Vertex Pharmaceuticals (VRTX) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.56%.For the last ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m. ET/8:15 a.m. PT. “ 2023 was marked by continued strong performance in the cystic fibrosis business and acceleration of our development stage pipeline, propelling the company into 2024 with tremendous momentum ...

Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals (VRTX 0.59%) is modeling right now.Thanks to its long-standing dominance in a key niche market, its newfound pursuit of powerful gene therapies, and its cash output, there's good reason to be excited about the stock. So here are three arguments for why it's worth buying now.1. Its base of recurring revenue is ro ...